Cancer Gene Therapy Market Size, Growth, Trends | Report 2022-2030
Cancer gene therapy has gained popularity in the last few years due to its high success rates during clinical and preclinical trials. The emerging field delivers a number of potential applications for cancer treatments. It offers various advances in the field of molecular biology, molecular genetics, immunology, virology, and molecular genetics. In various instances, this technique for cancer has been intended to augment existing therapies, such as immunotherapies and chemotherapies.
The cancer gene therapy approaches include oncolytic virotherapy, immunotherapy, and gene transfer. It can be utilized in different ways. For instance, altering gene regulation, replacing defective and missing genes with healthy genes, and introducing foreign genes into cells to change their function. The most common method is to replace a cancer-causing mutant gene with a healthy one.
Viral and non-viral vector products are needed for this technique. Non-viral vectors are normally utilized to transfer the different types of nucleic acids such as large DNA molecules ((Plasmid DNA: p DNA), small DNA, and RNA (m RNA, Si RNA, Ribozymes). Moreover, viral-vector therapies use modified viruses as drug-delivery vehicles to insert specific DNA sequences- regulatory RNAs (e.g. siRNAs), encoding genes, or other therapeutic substrates into cells.
Despite the slow clinical progress, researchers are undertaking efforts to develop specific non-toxic cancer therapies that are rising exponentially. As of now, more than 500 products under trial have been listed with the FDA. There is a number of strategies currently being followed during the cancer treatments. For instance,
The pipeline for cancer therapies is quite strong and various companies are engaged in developing efficient products. Small biopharma companies are also emerging in the cell and gene therapy industry. For instance, Autolus Therapeutics is developing AAV-based gene therapies. The company is targeting patients suffering from chronic, systemic diseases using this technique.
Moreover, improving the regulatory scenario is also expected to increase the product launch in the market. For instance, in March 2021, Bluebird Bio and Bristol Myers Squibb received FDA approval for Abecma (idecabtagene vicleucel). It is a cell-based gene therapy to treat patients with multiple myeloma.
In addition, in February 2022, the University of Pennsylvania doctors’ team announced that cancer patients treated with gene therapy in 2010 shows no sign of cancer in the body. The two examples demonstrate how the therapy, known as CAR-T cell therapy, can fight cancer right away inside the body, and evolve to battle against the tumor. Moreover, in July 2022, ImmunoACT, backed by Laurus Labs, announced that it tested a novel gene therapy cure for leukemia and lymphoma. The lab is working with CD19 CAR-T Cell for leukemia and lymphoma. According to the lab, findings begin to appear after about a week.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Gene Therapy Market
5.1. COVID-19 Landscape: Cancer Gene Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Gene Therapy Market, By Therapy
8.1. Cancer Gene Therapy Market, by Therapy, 2022-2030
8.1.1. Oncolytic Virotherapy
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Gene-induced Immunotherapy
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Gene Transfer
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cancer Gene Therapy Market, By End-user
9.1. Cancer Gene Therapy Market, by End-user, 2022-2030
9.1.1. Research Institutes
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Biopharma Companies
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Diagnostic Centres
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cancer Gene Therapy Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.1.2. Market Revenue and Forecast, by End-user (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.1.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.1.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.2.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.2.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.2.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.2.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.2.6.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.3.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.3.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.3.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.3.6.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.4.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.4.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.4.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.4.6.2. Market Revenue and Forecast, by End-user (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.5.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Therapy (2017-2030)
10.5.4.2. Market Revenue and Forecast, by End-user (2017-2030)
Chapter 11. Company Profiles
11.1. Abeona Therapeutics
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Asklepios BioPharmaceutical
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Celgene
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Elevate Bio
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. GlaxoSmithKline
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Bluebird bio
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Genelux Corporation
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. OncoGenex Pharmaceuticals
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Introgen Therapeutics
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Altor Bioscience
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers